Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) announced its earnings results on Wednesday. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by ($0.02), Zacks reports. The firm had revenue of $503.22 million during the quarter, compared to analysts' expectations of $507.19 million. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%.
Elekta AB (publ) Trading Down 5.0%
OTCMKTS EKTAY traded down $0.27 on Friday, reaching $5.22. The stock had a trading volume of 7,677 shares, compared to its average volume of 17,568. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 20.86 and a beta of 1.26. The company has a quick ratio of 0.81, a current ratio of 1.05 and a debt-to-equity ratio of 0.60. Elekta AB has a 12-month low of $4.36 and a 12-month high of $8.17. The stock has a fifty day moving average price of $5.05 and a two-hundred day moving average price of $5.46.
About Elekta AB (publ)
(
Get Free Report)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
Read More
Before you consider Elekta AB (publ), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.
While Elekta AB (publ) currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
